Advertisement
As the largest contraceptives market the US will experience moderate growth at a compound annual growth rate (CAGR) of 4.8% reaching $5.2bn total sales by 2027. This market offers several options including both on-demand and longer-acting approaches and has been dominated by intrauterine devices and oral contraceptives during the past decade.
Advertisement
Despite Twirla’s rocky regulatory history it will become the only low-dose combination hormonal contraceptive patch once it hits the market. Moreover as Twirla delivers a much lower dose of ethinyl estradiol per day compared to the only similar approved option namely the high-dose Xulane patch it could have an edge over Xulane.
Kelly Lambrinos Senior Pharma Analyst at GlobalData comments: “Compliance difficulties are more common among oral contraceptive users while other long-lasting forms such as hormonal intrauterine devices tend to cause various unwanted side effects. As there is a need in the female contraception space for a method that is not an inserted device or an ingested pill the demand for a novel weekly transdermal option will be evident and there is space for Twirla’s addition to the current US market.
“However there still remains a need for more alternatives and particularly non-hormonal options. Key opinion leaders (KOLs) interviewed by GlobalData have expressed that there are some women who remain hesitant in taking hormonal contraceptives because of the associated side effects.”